Hong Kong
Every Hong Kong biotech applicant has to tell investors what it will do with the money it raises. On the evidence of the twelve 18A application proofs that...
October 06, 2026 | Analysis
Akeso, Inc. announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating ...
September 29, 2026 | News
This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's ...
September 28, 2026 | News
- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...
September 24, 2026 | News
Akeso, Inc. announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat...
September 04, 2026 | News
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
September 04, 2026 | News
The Hong Kong Applied Science and Technology Research Institute (ASTRI) and Saint Francis University (SFU) have signed a Memorandum of Understanding (MoU) ...
August 26, 2026 | News
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue GenScript Biotech Corporation (HKEX: 154...
August 20, 2026 | Company results
Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced the nom...
August 14, 2026 | News
VMS Group, a global alternative investment specialist, announced that its portfolio company, Ommo Technologies (Ommo), a spatial intelligence tec...
August 13, 2026 | News
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) eval...
August 11, 2026 | News
Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Al...
August 06, 2026 | News
-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight acr...
August 05, 2026 | News
FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico's first FTD, recognizing the...
July 31, 2026 | News
Most Read
Bio Jobs
News